Stock Research for MNKD


Featured Broker: Ally Invest

Get the due diligence for another stock.


MNKD Stock Chart & Research Data

The MNKD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNKD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


MNKD Due diligence Resources & Stock Charts

The MNKD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MNKD Detailed Price Forecast - CNN Money CNN View MNKD Detailed Summary - Google Finance
Yahoo View MNKD Detailed Summary - Yahoo! Finance Zacks View MNKD Stock Research & Analysis -

Stock Analysis

TradeIdeas View MNKD Trends & Analysis - Trade-Ideas Barrons View MNKD Major Holders - Barrons
NASDAQ View MNKD Call Transcripts - NASDAQ Seeking View MNKD Breaking News & Analysis - Seeking Alpha
Spotlight View MNKD Annual Report - OTC Report View MNKD OTC Short Report -
TradeKing View MNKD Fundamentals - TradeKing Charts View MNKD SEC Filings - Bar Chart
WSJ View Historical Prices for MNKD - The WSJ Morningstar View Performance/Total Return for MNKD - Morningstar
MarketWatch View the Analyst Estimates for MNKD - MarketWatch CNBC View the Earnings History for MNKD - CNBC
StockMarketWatch View the MNKD Earnings - StockMarketWatch MacroAxis View MNKD Buy or Sell Recommendations - MacroAxis
Bullish View the MNKD Bullish Patterns - American Bulls Short Pains View MNKD Short Pain Metrics -

Social Media Mentions

StockTwits View MNKD Stock Mentions - StockTwits PennyStocks View MNKD Stock Mentions - PennyStockTweets
Twitter View MNKD Stock Mentions - Twitter Invest Hub View MNKD Investment Forum News - Investor Hub
Yahoo View MNKD Stock Mentions - Yahoo! Message Board Seeking Alpha View MNKD Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for MNKD - Insider Cow View Insider Transactions for MNKD - Insider Cow
CNBC View MNKD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MNKD - OTC Markets
Yahoo View Insider Transactions for MNKD - Yahoo! Finance NASDAQ View Institutional Holdings for MNKD - NASDAQ

Stock Charts

FinViz View MNKD Stock Insight & Charts - StockCharts View MNKD Investment Charts -
BarChart View MNKD Stock Overview & Charts - BarChart Trading View View MNKD User Generated Charts - Trading View

Latest Financial News for MNKD

MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target
Posted on Tuesday December 11, 2018

Zacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. MannKind Corporation (MNKD) was founded in the early 2000’s by the late Alfred Mann, a physicist by training, Mann was a pioneer in several fields including aerospace, electronics and medical devices. Among his successes prior to MannKind was development of the first rechargeable pacemaker and MiniMed, a revolutionary miniaturized insulin pump that was sold to Medtronic in 2001 for more than $3B.

Biotech Stocks Beating the Market
Posted on Monday December 10, 2018

HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Here are several biotech plays to pay close attention to in the coming sessions. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MannKind ...

MannKind Appoints Christine Mundkur to its Board of Directors
Posted on Tuesday November 27, 2018

MannKind Corporation (MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November 27, 2018.  Ms. Mundkur will also serve as a member of the Audit Committee of the Board. Ms. Mundkur brings 25 years of experience in the pharmaceutical industry to the MannKind Board. “Christine brings a tremendous wealth of experience to our board of directors,” said Kent Kresa, Chairman of the Board of MannKind Corporation.

Analysts: Why United Therapeutics has had a streak of licensing deals
Posted on Tuesday November 27, 2018

United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.